Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.
about
New Therapeutic Approaches in Polycythemia VeraLong-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosisManagement of polycythaemia vera: a critical review of current data.Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 MutationMulticenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.Polycythemia Vera Management and Challenges in the Community Health Setting.Pharmacological management of essential thrombocythemia.Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy.Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers.Mechanisms of thrombogenesis in polycythemia veraMyeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart reviewBleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.Novel and emerging therapies for the treatment of polycythemia veraTERT rs2736100 genotypes are associated with differential risk of myeloproliferative neoplasms in Swedish and Chinese male patient populations.From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management.Inherited predisposition to myeloproliferative neoplasmsEpidemiology of MPN: what do we know?Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study.Ruxolitinib for the treatment of patients with polycythemia vera.What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients.Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.Prognosis of Primary Myelofibrosis in the Genomic EraMyelofibrosis: an update on drug therapy in 2016.Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.Excess mortality in the myelodysplastic syndromes.Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera.
P2860
Q26795677-98E71BB3-F418-42BE-A320-FE946BB0087CQ27853043-2C0C41D2-3F45-40D3-948B-B07453956661Q31009757-9D4365D3-045C-4673-BA70-054195A49022Q33439559-E2B90C49-41B4-441B-B11B-BB25EA79D272Q33443246-D6CB3C25-16EC-48F5-80E8-F9A3BF27A297Q33747797-050D3F4C-0980-40FD-9201-1F8495A2A7EEQ33803036-6EC54941-5258-4DA5-8206-E364560BBC8BQ34344384-B0EF640D-08BF-4779-AD57-B184302390A7Q35032345-8F233121-310F-48BB-A1C0-F67AAD5EB335Q35117512-E5F3FE3C-0B17-49F9-8FBE-93C20D64CB78Q35525312-ED370519-94BC-4579-AA57-50AFDF7CC925Q35738656-8EB73A87-64DE-4B8F-BC65-5CF7C0FF8231Q35938283-B3274413-D4F7-4042-9994-C5DAF1ABFC83Q36305314-5ADC2369-D829-4FFC-9C39-9638725417A8Q36529881-184457B8-015A-4B65-8588-90DB927F6558Q36654317-2F577DBB-C700-4281-86D1-512442FD001DQ37069633-9DBAC420-0BA7-4619-B72F-92C3484D4D37Q37293282-6F3353C7-CA29-42D9-A20F-C290447AD004Q37555790-C010A97C-8E8E-496F-B0F3-060B947FEFF1Q37623539-FB8C7903-5592-4AA2-8FBC-4B7A4D709B9EQ37631854-E694740B-B5AA-4B5E-9655-D1CBBEB3F1DFQ37679175-8650966B-EF4F-4912-99C5-A9BEC992F54BQ37682689-DF2A85B3-802D-4B7F-B05C-D195AAC32B7CQ38100371-1691DB52-2BF0-4178-A08D-D2DEC3AAADCBQ38127417-65978ECA-3DDA-4C81-BC4A-B09D1090DA56Q38240406-A903978E-066B-4089-9FCF-A46C1FB6B189Q38255717-DD3A09C4-3940-484E-BC77-520ED5E9DC7EQ38393343-1A2E62B6-5D8D-466D-841D-5ED953882E77Q38424081-57E8D8CB-94EF-4069-AC50-319B587C0719Q38484321-1D1DC96B-C920-42DF-A169-16C07BCA8E5BQ38597994-06BBE804-2075-4A0C-AE89-D18ABAD00784Q38631064-76C0F09A-A79A-4C5C-A919-822A7A110322Q38706624-42511062-6258-4D61-AA0F-2224A6A93D43Q38926804-6036AC30-86BC-445D-A5E0-285C2E21940EQ38989215-CA3BB9BF-90EC-47DA-9377-10B8B837F4B7Q39513246-5543EEA7-500E-4D03-81DC-B221C7DDE1B9Q39661740-B6695A09-4FC9-42F3-AE50-3C8EE6EB9ED7Q40470007-4E186237-09F2-4F77-A634-A6D378126B91Q40497461-20A598A7-F6F9-4BCB-B194-186781F74AA6Q40544293-7465769B-0FDD-448B-86BB-1005D29145DE
P2860
Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Patterns of survival among pat ...... 008: a population-based study.
@ast
Patterns of survival among pat ...... 008: a population-based study.
@en
type
label
Patterns of survival among pat ...... 008: a population-based study.
@ast
Patterns of survival among pat ...... 008: a population-based study.
@en
prefLabel
Patterns of survival among pat ...... 008: a population-based study.
@ast
Patterns of survival among pat ...... 008: a population-based study.
@en
P2093
P2860
P50
P356
P1476
Patterns of survival among pat ...... 008: a population-based study.
@en
P2093
Asa Rangert Derolf
Magnus Björkholm
Sandra Eloranta
Sigurdur Yngvi Kristinsson
P2860
P304
P356
10.1200/JCO.2012.42.1925
P407
P577
2012-07-16T00:00:00Z